Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Girolomoni, Gampiero (University of Verona (Itàlia))
Feldman, Steven (Wake Forest University School of Medicine (Estats Units d'Amèrica))
Egeberg, Alexander (University of Copenhagen)
Puig Sanz, Lluís (Institut de Recerca Sant Pau)
Jung, Jin Ah (Samsung Bioepis (Seül))
Jung, Hojung (Samsung Bioepis (Seül))
Lee, Younju (Samsung Bioepis (Seül))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Background: SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate-to-severe chronic plaque psoriasis. Objectives: To assess the four-year persistence associated with the effectiveness and safety of SB5 in patients with psoriasis in the UK and Ireland. Methods: This prospective study included 1195 SB5-treated patients using British Association of Dermatologists' Biologic Interventions Register (BADBIR) between 01 June 2018 and 31 August 2022. Persistence was defined as the time from biologic therapy initiation to discontinuation and Kaplan-Meier analysis was used to evaluate SB5 discontinuation rates. Cox regression was used to investigate the effect of covariates on the time-to-first-discontinuation of SB5 with the potential covariates. Results: SB5 one-, two-, three-, and four-year discontinuation rates were 26. 5%, 37. 2%, 41. 9%, and 43. 3%, respectively. Tested covariates such as switching, age, sex, body mass index (BMI), and duration of psoriasis did not significantly affect the discontinuation rate of SB5. Conclusions: Median persistence of SB5 in predominantly bio-naïve psoriasis patients was about 2. 5 years in clinical practice. The results suggest that SB5 can be confidently used for patients with psoriasis, offering comparable outcomes to reference adalimumab.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adalimumab ; BADBIR ; SB5 ; Drug survival ; Psoriasis ; Real-world data ; Real-world evidence ; Registry
Publicat a:	Journal of Dermatological Treatment, Vol. 35 Núm. 1 (2024) , p. 2434091, ISSN 1471-1753

DOI: 10.1080/09546634.2024.2434091
PMID: 39626886

8 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats